

BRIDGING STUDIES IN PRECLINICAL PHARMACEUTICAL SAFETY ASSESSMENT

SHAYNE COX GAD

Gad Consulting Services, Cary, North Carolina

Contents

- 1 Introduction
 - 2 Causes and Solutions
 - 2.1 Formulation Changes
 - 2.2 Changes in Manufacturing Processes or Site
 - 2.3 Alterations in Proportions of Optical Isomers
 - 2.4 Issues of Test Species Selection
 - 2.5 Impurity and Degradant Issues
 - 2.6 Active Metabolite Issues
 - 2.7 Correlation of Effects Between Nonclinical Species
 - 2.8 Correlation of Surrogate Markers with Established Effects on Toxicity Indicators
 - 3 Issues of Bridging Study Design
 - 3.1 Test Compound(s)
 - 3.2 Basic Bridging Study Design
 - 3.3 Comparative (or Base) Species Data: Historical or Concurrent
- References

1 INTRODUCTION

Preclinical toxicology bridging studies are unique to the safety evaluation of pharmaceuticals [1–3]. While there have been analogues in clinical drug evaluation [4–6], only in the development of new drugs or new drug formulations are we faced with